Volansi
Winter 2017AcquiredAutonomous VTOL delivery solutions.
Pressure-test this opportunity
Explore the risks and possibilities with a prompt for ChatGPT, Claude, or your agent.
Autonomous VTOL delivery solutions.
Explore the risks and possibilities with a prompt for ChatGPT, Claude, or your agent.
Volansi built impressive long-range delivery drones and ran pilots with Merck, Boeing, and the U.S. military — and still ran out of runway before the market it needed could legally exist. Founded in 2015 in the San Francisco Bay Area by Hannan Parvizian and Wesley Zheng, it made vertical-takeoff-and-landing (VTOL) drones for middle-mile logistics: flying medical supplies, spare parts, and defense payloads long distances autonomously.[1]
The company raised roughly $75 million, including a $50 million round, and in March 2022 unveiled the VOLY 50, a long-range flexible-payload drone slated for low-rate production in 2023.[2][3] Months later it was gone: in July 2022 Volansi filed an assignment for the benefit of creditors and ceased operations.[1] The core problem wasn't the aircraft. It was that commercial drone delivery at scale required routine beyond-visual-line-of-sight flight the FAA had not yet authorized, so Volansi's revenue ceiling was set by a regulator's timeline while its burn was set by its own ambition.
Hannan Parvizian and Wesley Zheng founded Volansi (originally styled Volans-i) in 2015 to solve a real logistics gap: getting critical goods across the "middle mile" — tens or hundreds of miles between a warehouse or port and a remote site — faster and cheaper than trucks or helicopters.[5] For medical supplies to clinics, spare parts to ships or oil rigs, and resupply to military units, a fast autonomous aircraft could be transformative.
The founders bet on hybrid VTOL drones: aircraft that take off and land vertically like a helicopter but fly efficiently like a fixed-wing plane, giving both landing flexibility and long range. The vision attracted serious partners and capital — Volansi ran vaccine-delivery pilots with pharmaceutical giant Merck, drew investment interest from Boeing, and secured work with the U.S. Department of Defense.[6] These relationships validated that the capability was wanted. But they were pilots and contracts of exploration, not the scaled commercial volume the business needed, and the gap between "prestigious pilot" and "recurring revenue at scale" is where Volansi lived and eventually died.
Volansi built a family of autonomous VTOL cargo drones under the VOLY name. The aircraft could take off vertically from a small pad, transition to efficient winged flight to cover long distances, deliver a payload, and return — all autonomously, without a runway or a pilot on the sticks.[3] The final flagship, the VOLY 50, emphasized long range and a flexible payload bay so a single airframe could serve medical, commercial, and defense missions.[7]
The engineering was legitimate and the use cases compelling: delivering vaccines to hard-to-reach clinics, resupplying ships at sea, or moving parts to remote industrial sites. But building and iterating aircraft is expensive and slow, and each new model consumed capital while the path to flying them commercially at scale remained blocked. Volansi was developing hardware as fast as its funding allowed toward a market whose gate — routine long-range autonomous flight over populated areas — only a regulator could open.[8]
Volansi targeted enterprise and government buyers with remote-logistics pain: pharmaceutical and healthcare distribution, industrial and offshore operators, and the military — customers with real need and budget, but who bought in pilots and programs, not yet in fleets.
Middle-mile logistics is enormous, and autonomous aviation could address a valuable slice of it. But the near-term addressable market was tiny, throttled by regulation and confined to waivered pilots, while the large market lay years out.
Volansi competed with other drone-logistics startups (Zipline, Matternet, Wing), traditional logistics, and the inertia of trucks and helicopters.[4] The decisive competitive factor was not another company but the regulatory environment. Zipline succeeded partly by operating first in countries with permissive airspace and a narrow medical use case; Volansi's broader, U.S.-centric ambition ran straight into the FAA's cautious, slow path to routine beyond-visual-line-of-sight operations. In a market gated by a regulator, the winner is whoever can survive until the gate opens, and survival is a function of burn rate versus that timeline.
Volansi's model combined selling drone-logistics services, running customer programs, and defense contracts, with an eventual aim of scaled commercial operations and possibly aircraft sales.[6] The revenue was project- and pilot-based — meaningful for validation but far below what a hardware-heavy R&D operation required to sustain itself. With roughly $75 million raised and continuous aircraft development, Volansi spent like a company building toward mass deployment while earning like one running experiments. That mismatch is survivable only if scaled commercial revenue arrives before the money runs out, and for drone delivery in the U.S., the regulatory clock ran slower than the funding clock.
The central mechanism is a timeline mismatch the company could not control. Commercial drone delivery at scale required the FAA to permit routine long-range, beyond-visual-line-of-sight flight over populated areas — approvals that arrived slowly and piecemeal through waivers.[1] Volansi could build better aircraft, but it could not accelerate the regulator, so its scaled-revenue ceiling was externally fixed while its spending on aircraft R&D kept climbing. When a business's growth is gated by an authority's pace and its costs by its own roadmap, runway becomes the binding constraint, and Volansi's ran out in July 2022.
Merck vaccine trials, Boeing's interest, and defense work made Volansi look de-risked, but these were exploratory programs, not the recurring fleet contracts that fund a hardware company.[6] Treating prestigious pilots as proof of a scaled market is a recurring error in capital-intensive startups: the logos validate the capability while obscuring that no one is yet buying at volume. Volansi kept building toward mass production — the VOLY 50 was aimed at 2023 low-rate production — on the strength of demand that was still one regulatory unlock away.[3]
Volansi's struggle was not unique. U.S. drone delivery broadly stalled on the same regulatory bottleneck: Amazon's Prime Air repeatedly slipped, and most operators remained confined to limited trials.[4] The companies that made progress narrowed radically — a single medical use case, permissive foreign airspace, or defense applications with their own rules. Volansi's broad, flexible-payload ambition kept it exposed to the general U.S. regulatory timeline rather than escaping into a permitted niche, and that breadth, combined with hardware costs, left no way to outlast the wait.